Sandostatin (octreotide) solution for injections 0.05 mg/ml. 1ml. ampoules N5

$103.50

Acromegaly – to control the main manifestations of the disease and reduce the levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in the blood plasma in cases where there is no sufficient effect from surgical treatment and radiation therapy. Sandostatin is also indicated for the treatment of patients with acromegaly who have refused surgery or have contraindications to it, as well as for short-term treatment in between courses of radiation therapy until its effect fully develops. Relief of symptoms associated with endocrine tumors of the gastrointestinal tract (GI) and pancreas carcinoid tumors with the presence of carcinoid syndrome; Vipomas (tumors characterized by hyperproduction of vasoactive intestinal peptide) glucagon; Gastrinoma / Zollinger-Ellison syndrome-usually in combination with histamine H 2 receptor antagonists or proton pump inhibitors; insulinome (for the control of hypoglycemia in the preoperative period, as well as for maintenance therapy); somatoliberina (tumor, characterized by Hyper-production of the releasing factor growth hormone). Sandostatin is not an antitumor drug, and its use can not lead to a cure for this category of patients. Prevention of complications after pancreatic surgery. Stopping bleeding and preventing recurrence of bleeding from esophageal varicose veins in patients with liver cirrhosis-in combination with specific therapeutic measures, such as endoscopic sclerosing therapy.

Category: Manufacturer: Switzerland

Description

Sandostatin Composition and form of release
The active ingredient of Sandostatin is octreotide. The release form of this pharmaceutical preparation is a solution for injection, in ampoules.

Indications
This drug inhibits the increased formation of growth hormone (somatostatin), as well as the release of serotonin and peptides produced by the endocrine cells of the stomach, intestines, and pancreas.
Sandostatin is indicated for the following conditions:

  • acromegaly (in case of impossibility or ineffectiveness of the use of radiation therapy, surgical treatment or therapy with dopamine agonists);
  • endocrine tumors: glucagonomas, insulomas, VIPomas, gastrinomas;
  • tumors characterized by increased production of somatoliberin;
  • for the prevention of complications during operations on the pancreas;
  • refractory diarrhea (diarrheal syndrome) in AIDS;
  • bleeding (including prevention of relapse) from varicose veins of the esophagus in cirrhosis (emergency treatment).

Contraindications
Sandostatin is contraindicated in case of hypersensitivity to it.

Application during pregnancy and lactation
Caution is required when using the pharmaceutical preparation Sandostatin in women during the indicated periods.

Method of administration and dosage
With endocrine tumors of the digestive system and with acromegaly, the drug Sandostatin is administered at 0.05–1 mg subcutaneously once or twice a day. If necessary, it is possible to gradually increase the dose of this drug up to 0.2 mg three times a day.
In case of diarrheal syndrome in AIDS, the pharmaceutical preparation is administered at 0.1 mg subcutaneously three times a day. It is also allowed to gradually increase the dose of the drug to 0.25 mg three times a day.
For the prevention of complications after operations on the pancreas, the first dose of the drug (0.1 mg) is administered subcutaneously one hour before the intervention; further after the operation, Sandostatin is injected at 0.1 mg subcutaneously three times a day. At the indicated dosage, the drug should be administered within seven days.
In order to stop bleeding from varicose veins, this drug should be administered by continuous intravenous infusion at 25 mcg / hour for five days.
Before the introduction, the drug should be at room temperature.
It must be remembered that against the background of Sandostatin therapy in patients receiving insulin, a decrease in the need for it is possible. Therefore, such patients require regular monitoring of plasma glucose levels.

Overdose
Due to an overdose of Sandostatin, hypotension, weakness, pancreatitis, drowsiness, diarrhea, arrhythmia, brain hypoxia, hepatitis steatosis, weight loss, lactic acidosis, liver enlargement, cardiac arrest can develop.
In case of an overdose of Sandostatin, the patient undergoes symptomatic treatment.

Side effects
When using the pharmaceutical drug Sandostatin, side effects such as flatulence, anorexia, acute pancreatitis, vomiting, abdominal pain, diarrhea, liver dysfunction, nausea, signs of acute intestinal obstruction, the formation of gallstones (in case of prolonged use), impaired tolerance to glucose, hair loss, hyper- or hypoglycemia.
At the injection site, there may be a burning sensation, itching, swelling, pain, redness.

Storage conditions and periods
Store the drug Sandostatin in a place protected from light, inaccessible to children. The solution must be kept at a temperature of + 2… + 8 ° C.

The shelf life of Sandostatin solution is five years.